Boston Scientific Agrees to Acquire Silk Road Medical

June 18, 2024—Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Silk Road Medical, Inc., developer of a platform of products for transcarotid artery revascularization (TCAR) to treat carotid artery disease.

The purchase price is $27.50 per share, reflecting an enterprise value of approximately $1.16 billion. Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions.

The company noted that the TCAR system gained FDA approval in 2015 and is supported by several clinical studies demonstrating a reduced risk of stroke and other complications associated with traditional open surgery. The products sold by Silk Road Medical are the only devices commercially available for use during the TCAR procedure, advised Boston Scientific in the press release.

“The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease” stated Cat Jennings, President, Vascular, Peripheral Interventions, Boston Scientific, in the press release. “We believe the addition of this clinically differentiated technology to our vascular portfolio demonstrates our continued commitment to provide meaningful innovation for physicians who care for patients with peripheral vascular disease.”